Gelonghui, April 15 | Xinbang Pharmaceutical (002390.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 6.461 billion yuan, up 1.75% year on year; net profit attributable to shareholders of listed companies was 287 million yuan, up 28.02% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 268 million yuan, up 19.43% year on year; basic income per share was 0.15 yuan; it plans to distribute a cash dividend of 0.60 yuan (tax included) to all shareholders for every 10 shares.
信邦制药(002390.SZ)：2023年度净利润增28.02%至2.87亿元 拟10派0.6元
Xinbang Pharmaceutical (002390.SZ): Net profit increased by 28.02% in 2023 to 287 million yuan, plans to distribute 10.0.6 yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.